Zeb Booker - CbdMD Chief Officer
| YCBD Stock | USD 0.47 0.01 2.17% |
Executive
Zeb Booker is Chief Officer of cbdMD Inc
| Address | 8845 Red Oak Boulevard, Charlotte, NC, United States, 28217 |
| Phone | 704 445 3060 |
| Web | https://www.cbdmd.com |
CbdMD Management Efficiency
The company has return on total asset (ROA) of (0.1571) % which means that it has lost $0.1571 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3507) %, meaning that it created substantial loss on money invested by shareholders. CbdMD's management efficiency ratios could be used to measure how well CbdMD manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -2.13. The current year's Return On Capital Employed is expected to grow to -0.88. At present, CbdMD's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 167.5 K, whereas Non Current Assets Total are forecasted to decline to about 8.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Chau MBA | CytomX Therapeutics | N/A | |
| Marc Wilson | Crinetics Pharmaceuticals | 45 | |
| MBA Ashizawa | Bio Path Holdings | N/A | |
| Dr MBA | Soleno Therapeutics | N/A | |
| Lauren Budesheim | Soleno Therapeutics | N/A | |
| Anuj MD | Assembly Biosciences | 46 | |
| Shannon Ryan | Assembly Biosciences | N/A | |
| Amy CFA | Assembly Biosciences | N/A | |
| Richard Colonno | Assembly Biosciences | 74 | |
| Kristen MS | Soleno Therapeutics | 55 | |
| Thomas Rollins | Assembly Biosciences | 68 | |
| Daniel Hood | Achilles Therapeutics PLC | N/A | |
| Kristi Elliott | Capricor Therapeutics | N/A | |
| MD FACP | Moleculin Biotech | 72 | |
| Dawn Benson | CytomX Therapeutics | N/A | |
| Michael MD | Soleno Therapeutics | 50 | |
| James Taylor | Achilles Therapeutics PLC | 63 | |
| Garlan Adams | Crinetics Pharmaceuticals | N/A | |
| Patricia MPH | Soleno Therapeutics | 58 | |
| PharmD MBA | Soleno Therapeutics | N/A | |
| Marcia Belvin | CytomX Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.35 | ||||
| Return On Asset | -0.16 |
cbdMD Inc Leadership Team
Elected by the shareholders, the CbdMD's board of directors comprises two types of representatives: CbdMD inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CbdMD. The board's role is to monitor CbdMD's management team and ensure that shareholders' interests are well served. CbdMD's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CbdMD's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Zeb Booker, Chief Officer | ||
| Raymond Coffman, CoFounder Chairman | ||
| Kevin MacDermott, President | ||
| John Weston, Director Relations | ||
| Shannon Charles, Chief Officer | ||
| Francisco Mangual, Senior Sales | ||
| Robert Pettway, Director Relations | ||
| Bradley Whitford, Treasurer Officer | ||
| Ronan Kennedy, Principal CEO | ||
| Matthew Coapman, Chief Officer | ||
| Lance Blundell, General Counsel | ||
| David Johnson, Senior Development | ||
| Sibyl Swift, VP Affairs | ||
| Sybil Swift, VP CSO |
CbdMD Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CbdMD a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.35 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.94) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 3.45 M | ||||
| Shares Outstanding | 3.76 M | ||||
| Shares Owned By Insiders | 19.14 % | ||||
| Shares Owned By Institutions | 3.95 % | ||||
| Number Of Shares Shorted | 280.76 K | ||||
| Price To Earning | 17.62 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether cbdMD Inc is a strong investment it is important to analyze CbdMD's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CbdMD's future performance. For an informed investment choice regarding CbdMD Stock, refer to the following important reports:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in cbdMD Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CbdMD. If investors know CbdMD will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CbdMD listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.90) | Revenue Per Share 7.06 | Quarterly Revenue Growth (0.15) | Return On Assets (0.16) | Return On Equity (1.35) |
The market value of cbdMD Inc is measured differently than its book value, which is the value of CbdMD that is recorded on the company's balance sheet. Investors also form their own opinion of CbdMD's value that differs from its market value or its book value, called intrinsic value, which is CbdMD's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CbdMD's market value can be influenced by many factors that don't directly affect CbdMD's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CbdMD's value and its price as these two are different measures arrived at by different means. Investors typically determine if CbdMD is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CbdMD's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.